Ultragenyx Pharmaceutical Inc. buy Barclays PLC
Start price
24.11.25
/
50%
€28.40
Target price
24.11.26
€43.44
Performance (%)
-29.93%
Price
08.01.26
€20.60
Summary
This prediction is currently active. The prediction for Ultragenyx Pharmaceutical Inc. disappoints with a performance of -29.93%. This prediction currently runs until 24.11.26. The prediction end date can be changed by Barclays_PLC at any time. Barclays_PLC has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Ultragenyx Pharmaceutical Inc. | 22.619% | 22.619% |
| iShares Core DAX® | 2.659% | 4.844% |
| iShares Nasdaq 100 | 0.916% | -0.554% |
| iShares Nikkei 225® | 2.426% | 1.598% |
| iShares S&P 500 | 1.230% | 1.039% |
Comments by Barclays_PLC for this prediction
In the thread Ultragenyx Pharmaceutical Inc. diskutieren
Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target lowered by analysts at Barclays PLC from $81.00 to $50.00. They now have an "overweight" rating on the stock.
Ratings data for RARE provided by MarketBeat
Stopped prediction by Barclays_PLC for Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc.
Start price
Target price
Perf. (%)
€45.20
06.08.24
06.08.24
€74.24
06.08.25
06.08.25
-48.67%
07.08.25
07.08.25

